For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development | 2,587 | 2,361 | 2,593 | |
| General and administrative | 1,600 | 2,687 | 3,071 | |
| Total operating expense | 4,187 | 5,048 | 5,664 | |
| Loss from operations | -4,187 | -5,048 | -5,664 | |
| Interest expense-Nonrelated Party | 33 | 31 | 29 | |
| Interest expense-Related Party | 5 | 10 | 23 | |
| Grant income | - | - | 0 | |
| Change in fair value of other liabilities and derivatives-Nonrelated Party | -45 | 93 | 18 | |
| Change in fair value of other liabilities and derivatives-Related Party | -3 | 7 | 1 | |
| Other income (expense), net | 73 | 18 | -22 | |
| Total other income, net | 83 | -123 | -93 | |
| Loss before income taxes | -4,104 | -5,171 | -5,757 | |
| Income tax provision | 4 | 10 | 4 | |
| Net loss | -4,108 | -5,181 | -5,761 | |
| Net loss attributable to noncontrolling interest | - | -32 | -46 | |
| Net loss attributable to controlling interest | -4,108 | -5,149 | -5,715 | |
| Deemed dividend on warrants | -309 | -5,673 | 0 | |
| Net loss attributable to common stockholders | -4,417 | -10,822 | -5,715 | |
| Basic EPS | -0.43 | -2.21 | -1.99 | |
| Diluted EPS | -0.43 | -2.21 | -1.99 | |
| Basic Average Shares | 10,308,000 | 4,907 | 2,877 | |
| Diluted Average Shares | 10,308,000 | 4,907 | 2,877 | |
Calidi Biotherapeutics, Inc. (CLDWW)
Calidi Biotherapeutics, Inc. (CLDWW)